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ABSTRACT 
 
Asthma is one of the twenty-seven conditions that is a Prescribed Minimum Benefit condition 
that all Medical Aids have to cover (Council for Medical Schemes, 2015). The prevalence of 
asthma in Southern Africa is estimated to be about 8.1% (SA Pharmaceutical Journal, 2012). 
Asthma is a major cause of morbidity and mortality in people and therefore prescribing 
patterns are important to investigate. 
 
This research project looked at the prescribing patterns for asthma and compared it with the 
standard treatment guidelines for patients diagnosed with first time asthma which has been 
recorded by a private Medical Aid. The study looked at medications and recorded if they 
were prescribed according to the stepwise approach and standard treatment guidelines and if 
there are any areas where prescribing practises for asthma sufferers can be improved. This 
was done by analysing chronic application forms received by a private Medical Aid over a 
period of eight months. Descriptive statistics was used to summarise the demographic data 
and prescribing patterns. Prescribing patterns were analysed to determine any specific 
patterns for the different types of prescribers. Prescribing patterns were correlated with 
guidelines. Medication prescribed from the providers was reviewed and the total number of 
medication prescribed on each prescription for asthma was recorded. 
 
The total patient population for this study was 3639 patients; from this total 2953 patients 
were diagnosed with first time asthma following the stepwise approach for treatment. 686 
patients were diagnosed with first time asthma and did not follow the stepwise approach for 
treatment which was 19% of the patient population. The patients with co-morbidities whose 
treatment did not following the stepwise approach was 20% so the fact that patients 
diagnosed with other chronic conditions did not influence prescribing patterns too much 
compared to the whole patient population. 
 
In all age groups general practitioners followed the stepwise approach best but in all cases 
they had the most variation in terms of reasons why this provider type did not follow the 
stepwise approach. In the age group 0-4 years, pulmonologists followed the stepwise 
approach the worst but again these are specialists in pulmonology and may be seeing 
complicated patients. In the age group 5-11 years, paediatricians had the highest percentage 
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of prescriptions that did not follow the stepwise approach. In the age group 12 years and 
older, specialist physicians had the highest percentage of prescriptions that did not follow the 
stepwise approach. In the adult population other prescribers like gastroenterologists, 
neurologists and nephrologist may have diagnosed patients with asthma as they were treating 
these patients for other conditions. 
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1. INTRODUCTION 
 
Asthma is defined as a disease of diffuse airway inflammation which is caused by a variety of 
triggering stimuli, which results in partial or complete bronchoconstriction, which is 
reversible (DiPiro et al., 2011). Signs and symptoms of asthma include: dyspnoea, chest 
tightness, coughing, nocturnal awakening, tachypnoea, tachycardia and wheezing (Beers et 
al., 2006: DiPiro et al., 2011). Some patients show persistent changes in their airway 
structure. Asthma is a disease of increasing prevalence, which is a result of genetic 
predisposition and environmental interactions. Asthma is one of the most common chronic 
diseases seen in childhood. There is no cure for, or prevention of asthma. 
Immunohistopathological features include: cell infiltration by eosinophils, neutrophils, T-
helper type 2 lymphocytes, mast cells and epithelial cells. Diagnosis of asthma is based on 
history and a physical examination and is confirmed by using pulmonary/lung function tests 
(Beers et al., 2006: DiPiro et al., 2011).  
 
Factors influencing the development of asthma include host factors like genes predisposing to 
atopy (allergy), genes predisposing to airway hyper-responsiveness, obesity and gender. 
Environmental factors include: indoor allergens like house dust mites, furred animals, fungi, 
moulds and yeasts, outdoor allergens like pollens and fungi, infections, occupational factors 
like industrial chemicals and insecticides, tobacco smoking and diet (Lalloo et al., 2007).  
 
1.1 PREVALENCE 
 
The global prevalence of asthma ranges from 1% to 18% of the population in different 
countries (Bousquet et al., 2005). The prevalence of asthma in Southern Africa is estimated 
to be about 8.1% (SA Pharmaceutical Journal, 2012). The prevalence of asthma is increasing 
worldwide and surveys indicate that the majority of patients in developed and developing 
countries do not receive optimal care and are therefore not well controlled. Steps in the 
management of asthma to achieve goals are to establish the diagnosis of asthma, assess the 
severity, and implement an asthma treatment by setting goals for control, finding ways to 
prevent exacerbations and treat the asthma with pharmacotherapy and to achieve and monitor 
control of the asthma (Lalloo et al., 2007: Lalloo et al., 2013: Fireman et al., 2003:). 
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1.2 UNCONTROLLED ASTHMA 
 
There are roughly 3 million people who suffer with asthma in South Africa, and the national 
death rate is ranked as one of the highest in the world. About 5% of these patients have 
severe asthma which is uncontrolled despite being on maximal and optimised therapy (Dheda 
et al., 2015). In South Africa, approximately 8 - 10% of the population is asthmatic, South 
Africa is ranked fourth highest in terms of asthma mortality. Patients with difficult to control 
asthma consume a high percentage (up to 80%) of asthma-specific healthcare expenditure due 
to the high cost of hospitalisation, physician visits, and increased healthcare utilisation. There 
is considerable morbidity, and an economic burden to patients and the state from days lost 
from school or work (Dheda et al., 2015). 
 
Goals of asthma management include:  
- Achieve and maintain control of symptoms 
- Maintain normal activity levels including exercise 
- Maintain pulmonary function as close to normal as possible 
- Prevent asthma exacerbations 
- Avoid adverse effects from asthma medications 
- Prevent asthma mortality  
(Lalloo et al., 2007). 
 
Reasons for poor asthma control include: 
- Lack of adherence to controller medication 
- Inability to use inhaler or powder device correctly 
- Inadequate drug dosage 
- Ongoing allergen exposures 
- Uncontrolled allergic rhinitis/sinusitis 
- Gastro-oesophageal reflux 
- Psychosocial problems (family dysfunction, behaviour problems, depression) 
- Use of medications with adverse events (e.g. β-blockers, aspirin, non-steroidal anti-
inflammatories) 
- Incorrect diagnosis  
(Lalloo et al., 2007; DiPiro et al., 2011; Lalloo et al., 2013). 
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When asthma is first diagnosed it can be classified as mild intermittent or chronic persistent 
asthma that may be mild, moderate or severe (Figure 1.1). 
 
 
 
Figure 1.1 Assessment of asthma severity using symptoms of PEF in patients presenting 
for the first time on no treatment (Lalloo et al., 2007). 
 
Acute symptoms are episodic and are managed by self-medication with a reliever medication 
(inhalation of β2-agonists). The frequent use of reliever medication indicates suboptimal 
control and demands attention to controller treatment (DiPiro et al., 2011; Lalloo et al., 2007; 
Lalloo et al., 2013). 
 
1.3 EXACERBATIONS 
 
Asthma exacerbations are also referred to as acute asthma or asthma attacks, and result from 
frequent and progressive asthma symptoms and require early recognition to prevent 
morbidity and mortality. In some patients acute exacerbations may be of abrupt onset and 
progress rapidly to respiratory failure and death. An asthma exacerbation may be defined as a 
progressive or abrupt worsening in asthma symptoms, with increased use of bronchodilators 
with progressively decreasing response and/or a decrease in pulmonary function as measured 
by PEF or spirometry (Lalloo et al., 2013). 
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The features of acute asthma are due to widespread narrowing of the airways. The 
pathophysiology of airway narrowing is complex and includes: smooth muscle constriction, 
hypersecretion of mucous and mucous plugging of small airways, oedema of the airway wall 
with infiltration with inflammatory cells and disruption of the airway epithelium. 
 
1.4 DIAGNOSIS 
 
A brief history and physical examination should be conducted when the patient presents and 
at the same time treatment is initiated. A detailed history may follow once the patient is stable 
and should include the duration and severity of symptoms, exercise tolerance, sleep 
disturbance, all current medications (including devices and doses prescribed and taken), time 
of onset and cause of the present attack, possible triggers and presence of high-risk factors. 
The examination should assess the presence of any complications (e.g. pneumonia, lobar 
collapse or atelectasis and pneumothorax). Objective functional assessments such as baseline 
PEF or FEV1 and arterial oxygen saturation (SpO2) measurements (by pulse oximetry) 
before starting treatment should be routine. PEF measurement is preferred in emergency 
units, hospital wards, primary care clinics and general practitioner surgeries because it is 
widely available, simple, inexpensive, portable and safe. A baseline PEF measurement should 
be made before treatment is initiated (DiPiro et al., 2011; Lalloo et al., 2007; Lalloo et al., 
2013). 
 
Diagnostic lung function values include:  
- Reversibility: An increase of FEV1 of >12% and 200ml, 15-30 minutes after the 
inhalation of 200-400mcg salbutamol, or a 20% improvement in PEF from baseline 
shows reversibility and is an indication of asthma. 
- Hyper-responsiveness: methacholine/histamine challenge exercise: A fall of 20% in 
PEF (or 15% in FEV1) measured 5-10 minutes apart – before and then after cessation 
of exercise (e.g. running for 6 minutes). 
- Diurnal variation: diurnal variation in PEF of more than 20%. 
 
 
 
 
 
Page 14 of 56 
 
1.5 TREATMENT 
 
There are several classes of bronchodilators for acute asthma, each with a different mode of 
action and used sequentially depending on the response to treatment. They are presented in 
order of importance with a view to a stepwise approach to treatment (Lalloo et al., 2013). 
 
Asthma treatment includes reliever and controller medication. Reliever medication includes: 
 Short-acting β2-agonists: Include salbutamol and fenoterol. These medicines are used 
for quick relief of symptoms, and in acute attacks as a “when necessary” dosage only 
and have a short duration of action. This is the medicine of choice for relief of 
bronchospasm during an acute asthma exacerbation and for the pre-treatment of 
exercise-induced bronchoconstriction. 
 Short-acting inhaled anticholinergics. This includes ipratropium bromide which seems 
to be less effective than short-acting inhaled β2-agonists. Anticholinergics are 
alternative bronchodilator for patients, especially the elderly, who experience side-
effects from short-acting inhaled β2-agonists. 
 
Controller medication includes: 
 Inhaled corticosteroids: Include budesonide, beclomethasone, fluticasone and 
ciclesonide. They have an anti-inflammatory action to prevent asthma attacks and are 
the most effective controller medication. 
 Long-acting β2-agonists: Include formoterol and salmeterol. These medicines have a 
sustained bronchodilator action and are used in combination with inhaled 
corticosteroids. Formoterol has a more rapid onset of action than salmeterol. They 
should not be used as monotherapy as these medicines do not reduce airway 
inflammation. 
 Fixed combination inhalers: Include formoterol/budesonide and 
salmeterol/fluticasone. They achieve asthma control in more patients, more rapidly 
and at a lower dose of inhaled corticosteroids than inhaled corticosteroids used alone. 
Formoterol/budesonide may be used for both rescue and maintenance treatment 
(Barnes, 2007). 
 Leukotriene modifiers: They include montelukast and zafirlukast. They block the 
effects of leukotrienes in the airways. They are only used orally and show additive 
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effects when used with inhaled corticosteroids in mild to moderate asthma. They are 
less effective than long-acting β2-agonists as add-on therapy. They can be used as an 
alternative to inhaled corticosteroids in patients with mild asthma and some patients 
with aspirin-induced asthma. They can be used as an alternative first-line treatment 
for episodic or mild persistent asthma in children younger than five years. 
 Oral corticosteroids: They include prednisone, prednisolone and methylprednisolone. 
They are used for severely uncontrolled asthma. 
 Theophylline SR: This includes theophylline anhydrous. It has a modest anti-
inflammatory effect when given in a low dose. It is less effective than long-acting β2-
agonists. It has little effect as a first-time controller medication. Theophylline can be 
used as add-on therapy in patients who do not achieve control on inhaled 
corticosteroids alone (DiPiro et al., 2011; Lalloo et al., 2007; Lalloo et al., 2013; 
National Heart, Lung, and Blood Institute, 2007). 
 
Figure 1.2 is a summary of a treatment plan for asthma. Control needs to be assessed and 
treatment managed according to the control. The graph shows what to do when the patient is 
controlled and when the patient is not controlled and when to consult a specialist (Lalloo et 
al., 2007). 
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Figure 1.2 Algorithm for diagnosis and management of chronic asthma (Lalloo et al., 
2007). 
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The stepwise approach shows the medication to be used at each step for managing asthma 
which is recommended in the newest update by the National Asthma Education and 
Prevention Program (NAEPP). Non-pharmacological aspects are included in the therapy 
which is incorporated into steps. The guidelines were designed to give primary healthcare 
practitioners a framework with which to develop the proper approach to the individualised 
therapy for a patient. The focus of the therapy is the prevention and suppression of the 
underlying inflammatory process. The current therapeutic options in asthma consist of acute 
reliever medication which is used for acute exacerbations and long-term control medication 
which is used for the prevention of symptoms and exacerbations and for the suppression of 
inflammation. Therapy should be adjusted based on the control status of the patient (DiPiro et 
al., 2011).  
 
The three diagrams below will be used to indicate where the patient’s treatment fits in the 
stepwise guidelines and what medication the patient will need to help control the asthma and 
prevent exacerbations of symptoms. It also shows how to treat the patient if symptoms 
improve or if symptoms worsen. They are divided into the different age groups which were 
then used in the analysis. The age groups are 0-4 years, 5-11 years and 12 years and older. 
These tables were used to compare the prescribing patterns of healthcare providers in these 
age groups. What was prescribed and by whom and any trends in providers was reviewed. 
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Figure 1.3 Stepwise approach for managing asthma in children 0 to 4 years old (DiPiro 
et al., 2011).  
 
The main difference with the stepwise approach for children 0-4 years old is that theophylline 
is not included in the stepwise approach but is included from step two in the other age groups. 
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Figure 1.4 Stepwise approach for managing asthma in children 5 to 11 years old (DiPiro 
et al., 2011).  
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Figure 1.5 Stepwise approach for managing asthma in youths’ ≥12 years of age and 
adults (Copied from DiPiro et al., 2011).  
 
The Standard Treatment Guidelines for chronic persistent asthma includes: 
 General measures – patient education including advice on stop smoking. Decrease 
exposure to triggers such as grass, pets, dust mites, smoke, etc.  
 Medicine treatment – maintenance therapy includes inhaled corticosteroids which are 
the mainstay of treatment in chronic asthma. Reliever or rescue therapy includes β2-
agonists like salbutamol. If there is insufficient response to adequate steroids and 
salbutamol the doctor may add theophylline modified release tablets. If asthma is still 
not well controlled the doctor may add a short course of long acting β2-agonist 
therapy like formoterol. On failure of this therapy the doctor may add prednisone 
tablets (The National Department of Health, 2012). 
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2.  PROBLEM STATEMENT 
 
Asthma is one of the Prescribed Minimum Benefit (PMB) conditions, that if patients meet 
criteria, the condition may be registered as a chronic condition. First time applications 
submitted for asthma just diagnosed will be reviewed. There are guidelines which are not 
always adhered to (DiPiro et al., 2011; The National Department of Health, 2012). Interesting 
prescribing patterns have been seen when analysing chronic application forms and scripts for 
patients diagnosed with asthma for the first time. Reviewing prescriptions on a daily basis, 
patients just diagnosed with asthma and treated with two inhaled corticosteroids, or only a 
long acting β2 agonist or prescribed an oral corticosteroid for first time asthma is considered 
interesting. This research will be looking at whether prescribers are following treatment 
guidelines as patients need to receive the best treatment for managing their asthma according 
to current guidelines. The purpose of the study would be to see if medications are prescribed 
according to the stepwise approach and if there are any areas where prescribing practises for 
asthma sufferers can be improved. Some patients are not well controlled and we have to look 
at these reasons of non-compliance and review prescriptions to see any trends. 
 
3. AIM 
 
The aim of this research project is to document the prescribing patterns of asthma medication 
and to compare it with the standard treatment guidelines for patients diagnosed with first-time 
asthma as recorded by a private Medical Aid.  
 
Patients will be considered to have their asthma diagnosed for the first time if the date of 
diagnosis on their application form is in the time period March to October 2013 and the date 
the application was received shows this to be a recent diagnosis. Previous claims will be 
reviewed to remove patients who previously claimed asthma medication as acute medication 
before the application form was submitted. 
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4. OBJECTIVES 
 
1. To document patient demographics and prescribing patterns of patients diagnosed with 
first time asthma. 
2. To compare prescribing patterns with treatment guidelines. 
 
5. METHODOLOGY 
 
5.1 STUDY POPULATION 
 
During authorisation by the private Medical Aid the patient’s information is captured on the 
database. All personal and clinical information is captured under the member’s membership 
number which is updated and save when a new event, claim or consult occurs. Information 
gathered was based on the membership number where all of this information could then be 
found and was a reliable source. Information from study patients was retrospectively 
collected from the database. 
 
Patients who were diagnosed with first time asthma during the study time period (March to 
October 2013) were included. This was the time period where a lot of applications were 
received for asthma. Applications in the beginning of the year were mostly new members 
joining the medical aid with existing conditions which were excluded and fewer applications 
are seen towards the end of the year and are often because benefits have been depleted so 
patients apply and were patients with existing conditions. 
 
On the application form there was a column for doctors to complete which  indicated when a 
patient was diagnosed so the researcher will be able to see if it  was a recent diagnosis or not. 
Only patients who had been recently diagnosed were included in this study. Claims were 
reviewed to see when the patient started claiming their asthma medication. Medication 
prescribed was for ongoing treatment where medication was prescribed with no time limit. 
Acute medication prescribed for a short-term was not included in this study. This included 
corticosteroids and antibiotics approved for a few days as these medicines were not being 
used for the chronic treatment of asthma. 
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Both males and females were included in the study, as well as patients of all ages. Patients 
with other co-morbidities were also included in the study and other medication being claimed 
was recorded.  
 
Patients were excluded if their request for treatment was an update as they were previously 
diagnosed and because their medication may have changed in the past. 
 
Patient’s histories and physical examinations could not be reviewed from the data received 
for the study as no information from each of these consults was available or would have been 
received by the Medical Aid. 
 
5.2 DATA CAPTURING 
 
     5.2.1 DOCUMENT PATIENT DEMOGRAPHICS 
 
The patient’s age, gender, lung function tests (LFT) submitted, other tests, co-morbidities and 
other medication being claimed was documented. Severity of the condition was difficult to 
document. FEV1 improvement was documented if a lung function test had been submitted 
but other important information like symptoms, exacerbations, number of asthma attacks, 
how often patients used their reliever medication and experienced nocturnal symptoms could 
not be documented as this information was not available. 
 
     5.2.2 DOCUMENT PRESCRIBING PATTERNS 
 
Prescribing patterns from providers was documented and reviewed from the application 
forms or prescriptions. 
 
     5.2.3 DOCUMENT MEDICATION PRESCRIBED 
 
Type of asthma medication prescribed, the type of prescriber (e.g. general practitioner) and 
other medication the patient was claiming were documented.  
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5.3 DATA ANALYSIS 
 
Descriptive statistics were used to summarise the demographic data and prescribing patterns.  
Prescribing patterns were analysed to determine any specific patterns for the different types 
of prescribers.  
 
Prescribing patterns were compared with guidelines to see if the stepwise approach and 
Standard Treatment Guidelines were followed and to see if co-morbidities influenced the 
prescribing patterns. There are different steps or blocks on the stepwise approach and if the 
treatment prescribed corresponded to treatment in one of the blocks on the stepwise approach, 
the treatment was marked as following the stepwise approach. 
 
The stepwise approach divides the members into the age groups 0-4 years, 5-11 years and 12 
years and older. The age of the member in 2013 was used and if the patient was 4 turning 5 in 
2013 the age when the patient was diagnosed was used. 
 
Drug-interactions and contra-indications were reviewed according to the asthma medication 
approved and other medication being taken for other conditions. The number and type of 
interactions and indications were summarised and described. This was evaluated but viewing 
the medication the patient was prescribed and looking at references to check the interactions 
and contra-indications which included pharmacotherapy textbooks, the SAMF, package 
inserts and other references as indicated in the results. 
 
5.4 ETHICS 
 
Written consent to carry out the research was provided by this company. The Medical Aid 
and patient details was handled with strict confidentiality, no names or member numbers 
were used in the data collecting. The consent form given by the Medical Aid was not 
included for confidentiality reasons. 
 
A clinical analyst was consulted who extracted the patients diagnosed with first time asthma 
in the required time period from the database. The clinical analyst gave the member numbers 
to the researcher, who then was able to access all the information from her computer. No 
member numbers, names and personal information was documented. The clinical analyst uses 
Page 25 of 56 
 
data on a daily basis and kept information confidential. Once information had been extracted 
member numbers were deleted. 
 
The proposal was submitted to the University Ethics Committee and the Wits Postgraduate 
Committee for approval. The approvals are found under the appendices. 
  
6. RESULTS AND DISCUSSION 
 
A total of 9412 patients were approved for asthma from 1 March 2013 to 31 October 2013. 
After removing patients who joined the Medical Aid in these 8 months who were already 
diagnosed with asthma, 6849 patients were left. After further reviewing each application, 
looking at acute claims and previous medication claimed and reviewing the application for 
the date of diagnosis, there were a total of 3639 patients that were diagnosed with asthma for 
the first time. These 3639 patients were used to review the prescribing patterns of doctors and 
made-up our patient population. 
 
A total patient population for this study was expected to be 250 patients. However, a patient 
population of 3639 patients were evaluated. The reason for the vast difference in numbers 
expected and numbers received is the total population where these patients were taken from 
(in the medical aid) was much bigger than expected and this total population of the medical 
aid was underestimated.  
 
6.1 GENDER 
 
From the patient population 1853 (51%) are female (F) and 1786 (49%) are male (M).  
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Figure 6.1 Gender of patient population 
 
6.2 AGE 
  
The mean age of the patient population was 23.5 (SD: 23.39033785) years old. This had been 
divided into the age groups as used in the stepwise approach for asthma treatment. Fifty 
percent of the patients were younger than 12 years of age (Figure 6.2) with most of the 
patients less than five years.  
The over-all prevalence of asthma over the life-span indicates that the prevalence of current 
asthma peaked in the ten to twenty-four year old age-group. The prevalence of current asthma 
in those over 65 years has been documented in Australia as between 7.5 and 12.5%, with a 
predominance of females. Data from the USA suggests a prevalence between 4 and 10%, 
again with a predominance of females (Gillman, 2012). One of the controversies in the 
diagnosis of asthma in older people is the overlap with chronic obstructive airways disease so 
that a diagnosis of asthma is often considered less certain in this age-group (Gillman, 2012). 
Total, F, 1853, 51%
Total, M, 1786, 49%
Gender
F M
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Figure 6.2 Age groups of patient population 
 
The age groups were further divided and are presented in Figure 6.3. In the adult population 
the age group 31-40 years had the most number of patients. 
 
It was not expected to see a high number of patients diagnosed later on in life and this had 
been confirmed that only sixteen patients were diagnosed from 81-90 years old and only one 
patient was over 90 years old. However, an unexpected large number (1462 patients – 40%) 
of adult patients from 20 to 70 years of age received a first time prescription for chronic 
asthma.  
 
Differential diagnosis for adults with asthma may include chronic obstructive pulmonary 
disease (COPD), heart failure can cause a nocturnal cough and cardiac asthma, ischaemia 
heart disease (IHD) may be asthma or angina, malignancy, gastro-oesophageal reflux disease, 
pulmonary fibrosis, recurrent pulmonary embolism and tuberculosis. Out of all of these 
conditions only COPD, heart failure, IHD and asthma are Prescribed Minimum Benefit 
conditions and there is clinical entry criteria for COPD to be approved from the medical aid 
(Rull, 2010). 
1124, 31%
708, 19%
1807, 50%
0-4
5-11
12-Adult
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Figure 6.3 Age groups of patient population divided  
 
6.3 TYPE OF PRESCRIBER 
 
The majority of the chronic application forms came from general practitioners (49%), 31% 
from paediatricians, 10% from pulmonologists, 7% from specialist physicians and 3% of 
applications came from paediatric pulmonologists. The other healthcare providers made up 
0.7% (twenty-six patients) in total.  
 
The top five prescribers have been included in the graph below which include the majority of 
the prescriptions. No other literature reviewing the type of healthcare provider diagnosing 
asthma was found to compare this study to others. 
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Figure 6.4 Type of prescriber diagnosing asthma 
 
6.4 TOTAL MEDICATION PRESCRIBED 
 
Table 6.1 indicates the number of items prescribed. One to seven medicines were prescribed, 
the numbers highlighted in orange show the age group with the highest number in this group 
and the numbers highlighted in green shows the group with the fewest amount in this group. 
On average 2.2289 items were prescribed per prescription with a standard deviation of 
1.045320744. 
 
The age group 12 years and older had the most prescriptions with one and two items on the 
prescription. There were 1807 (50%) patients in this age group and 671 (37%) prescriptions 
had only one medication on it. This age group also had the most number of prescriptions 
where two items were prescribed 718 (40%). The age group 5-11 years had the fewest 
number of prescriptions (708). 55% of their prescriptions had one or two items prescribed. 
55% of the 0-4 year olds also had one or two items per prescription.  
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The 0-4 year old patients had the most number of prescriptions with three, four and five 
items. 27% (309) of prescriptions had three items, 15% (167) had four items and 3% (32) of 
prescriptions had five items. The total number of prescriptions for the age group was 1124. 
 
24% of prescriptions had three items on for the age group 5-11 years old. 19% had four items 
on the prescription which is the highest percentage in all age groups and 3% had five items 
prescribed for asthma. 
 
Reviewing the number of items on the prescription for the 12 years and older age group, 15% 
of prescriptions had three items, 6% had four items prescribed and 2% had five items 
prescribed. 
 
None of the prescriptions had six items on it but there was one prescription for the 12 years 
and older age group which had seven items prescribed for asthma. This prescription was from 
a general practitioner. 
 
When looking at treatment for patients diagnosed with asthma for the first time; one, two or 
three items can be explained, but prescribing five and seven medications for asthma is a lot. 
 
Table 6.1 Total medications prescribed per prescription per age group 
NUMBER OF MEDICATION 
ALL PATIENTS 
(%) 
0-4 YEARS 
(%) 
5-11 YEARS 
(%) 
12 YEARS AND 
OLDER (%) 
1 997 (27.4%) 188 (16.7%) 138 (19.5%) 671 (37.1%) 
2 1393 (38.3%) 428 (38.1%) 247 (34.9%) 718 (39.7%) 
3 754 (20.7%) 309 (27.5%) 168 (23.7%) 277 (15.3%) 
4 411 (11.3%) 167 (14.9%) 134 (18.9%) 110 (6.1%) 
5 83 (2.3%) 32 (2.8%) 21 (3.0%) 30 (1.7%) 
6 0 0 0 0 
7 1 (0.03%) 0 0 1 
Total 3639 (100%) 1124 (31%) 708 (19%) 1807 (50%) 
KEY: Green = least number, Orange = most number. 
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General practitioners prescribed a total of one or two medicines per prescription most 
frequently compared to the other healthcare providers. Three medicines per prescription were 
prescribed most frequently by paediatricians, paediatric pulmonologists prescribed four 
medicines per prescription the most and pulmonologists prescribed five medicines per 
prescription the most.  
 
One or two medicines per prescription was prescribed the least by paediatric pulmonologists 
and general practitioners prescribed three, four and five medicines per prescription the least 
compared to the other healthcare practitioners. 
 
When asthma is first diagnosed by a healthcare provider one or two medicines per 
prescription should be the most common as this is a first time diagnosis. If the initial 
treatment does not help then the provider should add medicine, a stepwise approach should 
be followed (DiPiro et al., 2011). An initial prescription of four and five medicines does not 
make sense and is not good practice. There are no other references where the number of 
medication can be viewed to compare this information. If a patient is not controlled, only 
then would more medication be added, so an initial prescription of five medicines does not 
make sense. 
 
Table 6.2. Total medications prescribed for each provider 
NUMBER OF 
MEDICATION 
GENERAL 
PRACTITIONER 
(%) 
PAEDIATRICIAN 
(%) 
PULMONOLOGIST 
(%) 
SPECIALIST 
PHYSICIAN 
(%) 
PAEDIATRIC 
PULMONOLOGIST 
(%) 
1 727 (41.3%) 105 (9.4%) 61 (16.4%) 83 (34.4%) 5 (4.2%) 
2 759 (43.1%) 383 (34.2%) 128 (34.3%) 97 (40.3%) 19 (16.1%) 
3 207 (11.8%) 390 (34.8%) 80 (21.4%) 43 (17.8%) 31 (26.3%) 
4 54 (3.1%) 209 (18.5%) 78 (20.9%) 15 (6.2%) 55 (46.6%) 
5 12 (0.7%) 34 (3.1%) 26 (7.0%) 3 (1.3%) 8 (6.8%) 
6 0 0 0 0 0 
7 1 (0.06%) 0 0 0 0 
TOTAL 1760 1121 373 241 118 
KEY: Green = least number, Orange = most number. 
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6.5 MEDICATION PRESCRIBED 
 
Reviewing medication prescribed is very important to ensure that patients are treated 
appropriately. Table 6.3 shows all the medication prescribed for the total population, per age 
group and as per the stepwise approach. 
 
Treatment for the initial diagnosis of asthma ideally should start with a short acting β2-
agonist as monotherapy or in combination with an inhaled corticosteroid only. Out of the 
3639 patient population there were 458 (12.6%) patients who were initially prescribed this 
treatment. 
 
Looking at the total patient population, inhaled corticosteroids in combination with long act 
β2-agonists was prescribed the most, which made up 898 (24.7%) of the total prescriptions. 
724 (19.9%) prescriptions included an inhaled corticosteroid, long acting β2-agonists and a 
short β2-agonist. 569 (15.6%) prescriptions had an inhaled corticosteroid with a short acting 
β2-agonist. 
 
242 (21.5%) prescriptions included an inhaled corticosteroid with a short acting β2-agonist in 
the 0-4 year old age group, 162 (14.4%) included an inhaled corticosteroid with a short acting 
β2-agonist and a leukotriene receptor antagonist. 148 (13.2%) prescriptions included an 
inhaled corticosteroid, long acting β2-agonist and a leukotriene receptor antagonist.  
 
In the 5-11 year old age group 172 (24.3%) prescriptions had an inhaled corticosteroid with a 
short acting β2-agonist and a leukotriene receptor antagonist prescribed, 128 (18.1%) 
prescriptions included an inhaled corticosteroid with a long acting β2-agonist and 124 
(17.5%) prescriptions had an inhaled corticosteroid prescribed with a short acting β2-agonist. 
 
In our final age group which included the greatest number of prescriptions, 668 (37%) 
prescriptions had an inhaled corticosteroid prescribed with a long acting β2-agonist, 441 
(24.4%) prescriptions included an inhaled corticosteroid, long acting β2-agonist and a short 
acting β2-agonist and 203 (11.2%) prescriptions had an inhaled corticosteroid prescribed with 
a short acting β2-agonist. 
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Leukotriene receptor antagonists were prescribed in more children than in adults. Leukotriene 
receptor antagonists are on the stepwise approach from step two. 
 
Table 6.3 Combination of medication prescribed 
 
ALL 
PATIENTS  
AGE 
0-4 
YEARS 
AGE 5-
11 
YEARS 
AGE 12 
YEARS AND 
OLDER 
MEDICATION TOTAL TOTAL TOTAL TOTAL 
Anticholinergic 12 2 2 8 
ICS 176 56 41 79 
ICS, Anticholinergic 17 6 1 10 
ICS, LABA 898 102 128 668 
ICS, LABA, Anticholinergic 54 3 3 48 
ICS, LABA, LTRA  309 148 69 92 
ICS, LABA, LTRA, Anticholinergic 6 0 1 5 
ICS, LABA, LTRA, Oral steroid 3 0 0 3 
ICS, LABA, Methylxanthine 9 0 0 9 
ICS, LABA, Methylxanthine, Anticholinergic 3 0 0 3 
ICS, LABA, Methylxanthine, LTRA 5 0 0 5 
ICS, LABA, Methylxanthine, LTRA, Anticholinergic 2 0 0 2 
ICS, LABA, Methylxanthine, LTRA, Oral steroid 1 0 0 1 
ICS, LABA, Methylxanthine, Oral steroid 2 0 0 2 
ICS, LABA, Methylxanthine, Oral steroid, Anticholinergic 1 0 0 1 
ICS, LABA, Oral steroid  6 0 0 6 
ICS, LABA, Oral steroid, Anticholinergic 1 0 0 1 
ICS, LTRA 88 68 17 3 
ICS, LTRA, Anticholinergic 8 6 1 1 
ICS, Methylxanthine 2 0 0 2 
LABA 10 1 1 8 
LABA, Anticholinergic 1 0 0 1 
LABA, Oral steroid 1 0 0 1 
LTRA 176 113 33 30 
LTRA, Anticholinergic 4 3 0 1 
LTRA, Oral steroid 2 0 0 2 
Methylxanthine 7 0 0 7 
Methylxanthine, Anticholinergic 1 0 0 1 
Methylxanthine, Oral steroid 1 0 0 1 
Oral steroid 2 0 0 2 
SABA 64 5 15 44 
SABA, Anticholinergic 1 0 0 1 
SABA, ICS 569 242 124 203 
SABA, ICS, Anticholinergic 2 1 0 1 
SABA, ICS, LABA 724 111 172 441 
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ALL 
PATIENTS  
AGE 
0-4 
YEARS 
AGE 5-
11 
YEARS 
AGE 12 
YEARS AND 
OLDER 
MEDICATION TOTAL TOTAL TOTAL TOTAL 
SABA, ICS, LABA, Anticholinergic 9 0 0 9 
SABA, ICS, LABA, LTRA 134 54 45 35 
SABA, ICS, LABA, LTRA, Anticholinergic 1 0 0 1 
SABA, ICS, LABA, Methylxanthine  17 0 1 16 
SABA, ICS, LABA, Methylxanthine, Anticholinergic 1 0 0 1 
SABA, ICS, LABA, Methylxanthine, LTRA 1 0 0 1 
SABA, ICS, LABA, Methylxanthine, LTRA, Anticholinergic 1 0 0 1 
SABA, ICS, LABA, Oral steroid 2 0 0 2 
SABA, ICS, LTRA 210 162 34 14 
SABA, ICS, LTRA, Anticholinergic 1 0 1 0 
SABA, ICS, Methylxanthine 8 0 0 8 
SABA, ICS, Oral steroid 2 0 1 1 
SABA, LABA 1 1 0 0 
SABA, LTRA 51 37 11 3 
SABA, Methylxanthine  2 0 0 2 
SABA, Methylxanthine, Anticholinergic 1 0 0 1 
SABA, Oral steroid 1 0 1 0 
No medicine for asthma prescribed 28 3 6 19 
KEY: ICS = Inhaled corticosteroid, LABA = long acting β2-agonist, LTRA = Leukotriene 
receptor antagonist, SABA = short acting β2-agonist 
 
Looking at the chronic application forms submitted, 1267 patients were diagnosed with 
allergic rhinitis on the same application form and the doctor requested either an anti-
histamine or a nasal corticosteroid or both when submitting the prescription for asthma 
medication.  
 
6.6 DRUG INTERACTIONS AND CONTRA-INDICATIONS 
 
There is an increased prevalence of asthma with increased use of paracetamol (DiPiro et al., 
2011). Bronchospasms can be induced by a wide variety of medications including penicillins, 
sulphonamides, cephalosporins, N-acetylcysteine, aspirin, non-steroidal anti-inflammatories, 
cimetidine and narcotic analgesics. B-adrenergic receptor blockers are medicines that can be 
harmful to patients with asthma. The more cardioselective agents like acebutolol and atenolol 
may also cause asthma attacks (DiPiro et al., 2011). 
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There were a total of 2583 (71%) patients who had been prescribed or dispensed a medication 
which can increase the prevalence of asthma or may be harmful to patients with asthma and 
may cause bronchospasms. This is the majority of the patient population. This is not to say 
this will happen but doctors and pharmacists need to be aware of it to treat patients and 
prevent bronchospasms in patients. It may also be the cause of the bronchospasms in some 
patients so a proper patient history is necessary. B-adrenergic receptor blockers should be 
avoided in patients with asthma (Frishman, 2003). There were 175 patients who were 
dispensed a B-adrenergic receptor blocker. These patients would need to be reviewed and see 
if more appropriate hypertensive medication can be used to best manage asthma with the 
other co-morbidities.  
 
Drug interactions with salbutamol include digoxin or diuretics where there is an increased 
risk of cardiac arrhythmias (Ventolin package insert, 2014), Symbicord (budesonide and 
formoterol) used with anti-arrhythmias, phenothiazides, MAOIs, tricyclic antidepressants and 
antihistamines can prolong the QTc interval and increase the risk of ventricular arrhythmias 
(SAMF, 2010). Sympathomimetic agents in combination with theophylline may potentiate 
cardiac effects (Das Pial, 2015). 
 
Salbutamol was prescribed for 1775 patients. There were four patients who were prescribed 
salbutamol with digoxin. Two of those were prescribed by specialist physicians and the other 
two by general practitioners. There were 121 patients who were prescribed salbutamol with a 
diuretic. Seventy-two of those were from general practitioners, one was from a paediatrician, 
33 were from pulmonologists, one was from a rheumatologist and fourteen were from 
specialist physicians. 
 
Out of the 326 patients prescribed budesonide and formoterol a total of 163 patients were also 
prescribed a medicine which has a drug interaction with budesonide and formoterol in 
combination. These included anti-arrhythmias, phenothiazides, MAOIs, tricyclic 
antidepressants and antihistamines (SAMF, 2010). There may be more patients prescribed 
these medicines together as patients can buy antihistamines over-the-counter. It is important 
for doctors and pharmacists to get a good patient history and to find out all other medicine the 
patient is taking to avoid drug interactions. 
 
Page 36 of 56 
 
There were a total of 64 patients who were prescribed theophylline. Twenty-four of those 
were prescribed theophylline with a sympathomimetic. It is important for all doctors treating 
patients to find out what medication they are taking to prevent drug interactions. It is 
important for pharmacists to ask patients what medication they are taking as a lot of these 
medicines are dispensed over-the-counter without a prescription. This number may be higher 
as not all medication taken over-the-counter will be claimed through the medical aid and 
therefore this data will not be included. 
 
Anticholinergics do not have a FDA label indication for asthma. Ipratropium bromide is only 
indicated in acute severe asthma not completely responsive to β2-agonists alone as it does not 
improve outcomes in chronic asthma and is therefore not on the stepwise approach and 
should not be prescribed for patients diagnosed with first time asthma (DiPiro et al., 2011). 
There were 150 patients prescribed an anticholinergic on their initial prescription. 
 
6.7 TESTS 
 
In the patient population only 218 (6%) patients had a lung function test submitted with their 
application. When diagnosing asthma, doctors will be looking at the reversibility and the 
percentage improvement of FEV1 post bronchodilator. Twenty-one patients diagnosed with 
asthma the FEV1 readings post bronchodilator decreased and had a negative value. This is 
unusual as FEV1 post bronchodilator should improve by more than 12% to show reversibility 
and to diagnose asthma (Lalloo, 2007). The doctor would have to see the whole patient 
profile and see if there was a different reason for the poor result like the member was tired 
and did not have a proper seal around the machine when blowing into it when performing the 
lung function test. These results would need to be questioned as they do not indicate asthma. 
Of the twenty-one prescriptions, nine were from a specialist physician, ten from a 
pulmonologist and two from a general practitioner.  The post bronchodilator FEV1 of 73 
patients improved up to 9% and 123 patients by 10% or more. 88 patients had a FEV1 
improvement of greater than 12% which would indicate asthma. 
 
It is difficult to perform lung function tests on children and therefore is hard to diagnose 
asthma based on lung function in children younger than 5 years. It is difficult to know 
whether young children who wheeze or have other asthma symptoms will benefit from long-
term control medicines. Quick-relief medicines tend to relieve wheezing in young children 
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whether they have asthma or not (National Heart, Lung, and Blood Institute, 2014). The lung 
function tests submitted were all for adults 35 years and older. 
 
 
Figure 6.5 Lung function test submitted 
 
According to the claim records, only 1400 (38%) patients had other tests done prior to being 
diagnosed with asthma (Figure 6.6). The tests included flow volume tests (624), x-ray of the 
chest (735), carbon monoxide diffusing capacity (37), peak expiratory flow (99), allergy: 
skin-prick tests (163),  IgE: total (208), determination of resistance to airflow (80), functional 
residual capacity (52), evaluation of bronchospasm (20), thoracic gas volume (32), IgE 
screening test for atopy (36), antigen specific IgE (58), combined antigen specific IgE (13), 
pulmonary stress testing (9), N2 single breath distribution (5), maximum 
inspiratory/expiratory pressure (2), forced expirogram (13) and allergy: patch tests (10). 
These tests help to make a diagnosis of asthma. This is not to say that the rest of the patients 
had no tests done; only tests submitted to the medical aid could be seen and included. 
 
The graph below shows the number of patients who had a lung test or procedure done. 
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Figure 6.6 Tests performed  
 
6.8 CO-MORBIDITIES 
 
Chronic conditions approved by the Medical Aid were included in the data as these were co-
morbidities that were recorded. Out of the 3639 patient population there were 2934 (81%) 
patients who do not have any other chronic conditions approved. There were 705 (19%) 
patients who have other chronic co-morbidities approved which included hyperlipidaemia, 
hypertension, diabetes type 2, ischaemic heart disease, ankylosing spondylitis, major 
depression, arthropathic psoriasis, atrial fibrillation and atrial flutter, congestive heart failure, 
rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), hypothyroidism, 
glaucoma, chronic kidney disease, bipolar affective disorder, epilepsy, stroke, schizophrenia, 
diabetes type 1, ventricular tachycardia, systemic lupus erythematosus, bronchiectasis, 
cardiac arrhythmia, cystic fibrosis, menopause, cardiomyopathy, ulcerative colitis, pulmonary 
embolism, congenital mitral stenosis, Parkinson’s disease, emphysema, generalized anxiety 
disorder, osteoporosis, HIV, hypopituitarism, and primary adrenocortical insufficiency. 
 
Test performed, 
1400, 38%
No test performed, 
2239, 62%
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Of these 705 patients, 139 patients were prescribed treatment which did not follow the 
stepwise approach. These included prescriptions from cardiologists, specialist physicians, 
Otorhinolaryngologists (ENT’s), nephrologists, paediatricians, paediatric pulmonologists, 
pulmonologists and general practitioners. The mean age of these patients was 59 years (SD: 
14.45226513). 20% of this patient population did not follow the stepwise approach, in most 
cases it is because the doctor prescribed an anticholinergic or because the doctor prescribed a 
long acting β2-agonist with theophylline and a leukotriene receptor antagonist. Twenty-nine 
patients had other reasons including a long acting β2-agonist prescribed without an inhaled 
corticosteroid. The prescriptions that stand out include eight patients prescribed medication to 
treat allergies only. The other conditions these patients are diagnosed with include human 
immunodeficiency virus (HIV), hypertension, menopause, hyperlipidaemia, chronic 
ischaemic disease and diabetes type 2. N-acetylcysteine (Acc200) was prescribed with 
theophylline and salbutamol for a patient diagnosed with congestive heart failure. 
Theophylline was prescribed with prednisone for a patient who was diagnosed with 
rheumatoid arthritis, the prednisone could then be used for both conditions and it was 
prescribed from a specialist physician. The other interesting one was oxygen prescribed as 
monotherapy for asthma for an 88 year old with glaucoma from a specialist physician. This 
patient would still need medication to control or relieve symptoms of asthma.  
 
The stepwise approach is a guide for treatment of patients with asthma. 2953 (81%) patients 
were diagnosed with first time asthma following the stepwise approach for treatment. 686 
(19%) patients were diagnosed with first time asthma and did not follow the stepwise 
approach. This was further broken down into the different age groups. Ages 0 - 4 years had a 
total of 884 (79%) following the stepwise approach and 240 patients (21%) not following the 
stepwise approach for treatment. Ages 5 - 11 years had 574 patients following the stepwise 
approach and 134 patients (19%) not following the stepwise approach for treatment. Ages 12 
– adult had 1494 patients following the stepwise approach and 312 patients (17%) not 
following the stepwise approach for treatment (DiPiro et al., 2011). 
 
6.9 ADHERENCE TO THE STEPWISE APPROACH 
 
The graph below shows the number of patients who had treatment prescribed from doctors 
for asthma who did follow the stepwise approach and the number of patients whose treatment 
did not follow the stepwise approach; this has been divided into the different age groups. 
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Patients who followed the stepwise approach had medication prescribed according to one of 
the steps from one to six on the stepwise approach. Patients were marked as not following the 
stepwise approach when their medication prescribed was not one of the steps on the stepwise 
approach. 
 
 
Figure 6.7 Number of patients following and not following the stepwise approach 
 
The providers for each of these age groups were reviewed. Each prescriber was looked at 
individually to see how many of their patients were treated using the stepwise approach for 
treating asthma. This was further broken down to see the reason the prescription did not 
follow the stepwise approach.  
 
For ages 0 – 4 years, general practitioners, paediatric pulmonologists, paediatricians and 
pulmonologists diagnosed asthma and prescribed treatment for these patients. A general 
practitioner motivated for 295 patients. Of those 36 (12%) did not follow the stepwise 
approach with their treatment, twenty-three patients were prescribed a long acting β2-agonist 
with a montelukast. On the stepwise approach patients should be prescribed either a long 
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acting β2-agonist or montelukast. Seven patients did not follow the stepwise approach as 
anticholinergics are not on the stepwise approach for treatment but these patients were 
prescribed an anticholinergic. The other reasons the patients did not follow the stepwise 
approach include a long acting β2-agonist prescribed with no inhaled corticosteroid, only 
medication used for allergies was prescribed, two inhaled corticosteroids prescribed and 
combinations of these reasons above (DiPiro et al., 2011). 
 
Paediatric pulmonologists prescribed treatment for 72 patients of which twelve (17%) 
patients’ treatment did not follow the stepwise approach for treatment as the doctor 
prescribed a long acting β2-agonist with a montelukast. On the stepwise approach patients 
should be prescribed either a long acting β2-agonist or montelukast.  
 
Paediatricians prescribed treatment for 746 patients of which 189 patients’ (25%) treatment 
did not follow the stepwise approach. The treatment for 164 patients did not follow the 
stepwise approach as the doctor prescribed a long acting β2-agonist with a montelukast. 
Treatment for twenty-one patients did not follow the stepwise approach as anticholinergics 
were prescribed and anticholinergics are not included on the stepwise approach. The other 
reasons treatment did not follow the stepwise approach include hydroxyzine prescribed which 
is not on the stepwise approach, only nasal corticosteroids prescribed and combinations of the 
reasons above. 
 
Pulmonologists prescribed treatment for eleven patients of which three patients’ (27%) 
treatment did not follow the stepwise approach. The two reasons treatment did not follow the 
stepwise approach include the doctor prescribed a long acting β2-agonist with a montelukast 
and anticholinergics prescribed for asthma and anticholinergics are not included on the 
stepwise approach. 
 
Table 6.4 shows the reasons the prescriptions from different providers did not follow the 
stepwise approach for the 0-4 year age group.  
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Table 6.4 Age 0 – 4 reasons providers did not follow the stepwise approach 
PROVIDER 
REASON PRESCRIPTION DID NOT FOLLOW THE STEPWISE 
APPROACH 
TOTAL 
General 
practitioner 
LABA or montelukast and patient has both 23 
Anticholinergic not on treatment guidelines 7 
LABA prescribed with no ICS 2 
Only meds for allergies prescribed 1 
2 ICS prescribed 1 
Anticholinergic not on treatment guidelines, 2 ICS prescribed 1 
LABA or montelukast and patient has both, 2 ICS prescribed 1 
Paediatric 
pulmonologist 
LABA or montelukast and patient has both 
12 
Paediatrician 
Anticholinergic not on treatment guidelines 21 
Hydroxyzine not on the treatment guidelines 1 
LABA or montelukast and patient has both 164 
LABA or montelukast and patient has both, Anticholinergic not 
on treatment guidelines 1 
Only a nasal steroid prescribed 2 
Pulmonologist 
LABA or montelukast and patient has both 1 
Anticholinergic not on treatment guidelines 2 
KEY: LABA = Long acting β2-agonist, ICS = Inhaled corticosteroid  
 
For ages 5 – 11 years old; general practitioners, paediatric pulmonologists, paediatricians, 
pulmonologists and specialist physicians diagnosed asthma and prescribed treatment for these 
patients. Three hundred and two patients were diagnosed and treated by general practitioners. 
Of the 302 patients, 37 (12%) of patients’ treatment did not follow the stepwise approach. 
Treatment of twenty seven of these patients did not follow the stepwise approach as the 
doctor prescribed a long acting β2-agonist with a montelukast. The other reasons include 
anticholinergics prescribed which are not on the stepwise approach, two inhaled 
corticosteroid prescribed for the patient, a long acting β2-agonist prescribed with 
theophylline, oxymetazoline (Iliadin) and betamethasone (Betnesol) prescribed which are not 
included on the stepwise approach, long acting β2-agonists prescribed as monotherapy, only 
medication indicated for allergies prescribed, oral corticosteroids prescribed without a long 
acting β2-agonist or montelukast and oral corticosteroids prescribed without an inhaled 
corticosteroid. 
 
Paediatric pulmonologists prescribed treatment for 40 patients of which treatment for seven 
patients (18%) did not follow the stepwise approach. The reason for four of these patients 
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was because the doctor prescribed a long acting β2-agonist with a montelukast. The other 
reasons include anticholinergics prescribed which are not included on the stepwise approach 
and one prescription only included medication used to treat allergies. 
 
Paediatricians prescribed treatment for 343 patients of which 88 (26%) prescriptions did not 
follow the stepwise approach. Patients’ treatment did not follow the stepwise approach as the 
doctor prescribed a long acting β2-agonist with a montelukast. The other reasons include 
anticholinergics prescribed which are not included on the stepwise approach, one prescription 
only included medication used for allergies and a combination of the reasons above. 
 
Pulmonologists prescribed treatment for nineteen patients of which treatment for two patients 
(11%) did not follow the stepwise approach. The two reasons these prescriptions did not 
follow the stepwise approach are the doctor prescribed a long acting β2-agonist with a 
montelukast and anticholinergics were prescribed which are not included on the stepwise 
approach. 
 
Specialist physicians prescribed treatment for four patients and all of these prescriptions 
followed the stepwise approach for treatment. 
 
Table 6.5 indicates the reasons the prescriptions from different providers did not follow the 
stepwise approach for the 5-11 year age group.  
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Table 6.5 Age 5 – 11 reasons providers did not follow the stepwise approach 
PROVIDER REASON PRESCRIPTION DID NOT FOLLOW THE STEPWISE APPROACH TOTAL 
General 
practitioner 
Oxymetazoline (Iliadin) and Betamethasone sodium phosphate 
(Betnesol) are not on treatment guidelines, anticholinergic not on 
treatment guidelines 1 
Anticholinergic not on treatment guidelines 2 
2 ICS prescribed 1 
LABA or montelukast and patient has both 27 
LABA or theophylline and patient has both 1 
LABA prescribed as monotherapy 1 
Only allergy meds prescribed for asthma 2 
Oral corticosteroid prescribed with ICS, no LABA or montelukast 1 
Oral corticosteroids without ICS 1 
Paediatric 
pulmonologist 
Anticholinergic not on treatment guidelines 1 
LABA or montelukast and patient has both 4 
Only meds for allergy prescribed 2 
Paediatrician 
Anticholinergic not on treatment guidelines 4 
LABA or montelukast and patient has both 82 
LABA or montelukast and patient has both, Anticholinergic not on 
treatment guidelines 1 
Only meds for allergy prescribed 1 
Pulmonologist 
LABA or montelukast and patient has both 1 
Anticholinergic not on treatment guidelines 1 
KEY: LABA = Long acting β2-agonist, ICS = Inhaled corticosteroid  
 
When looking at the ages twelve years and older this makes up the biggest patient population 
and has the most variation in terms of prescriber types. General practitioners prescribed 
medication for asthma for 1163 patients in this group which is the most by far. Of these 1163 
patients 151 prescriptions did not follow the stepwise approach which is 13% of the patients. 
The most common reason the medication prescribed did not follow the stepwise approach 
was the doctor prescribed anticholinergics which are not included on the stepwise approach. 
This included 51 prescriptions. The second most common reason was the doctor prescribed a 
long acting β2-agonist with a leukotriene receptor antagonist which included 48 
prescriptions. Seventeen treatments did not follow the stepwise approach as the doctor 
prescribed a long acting β2-agonist with theophylline. Other reasons treatment did not follow 
the stepwise approach include two inhaled corticosteroids prescribed on one prescription, N-
acetylcysteine (Acc200) was prescribed for asthma which is not on the stepwise approach, 
two long acting β2-agonists prescribed, long acting β2-agonists prescribed without an inhaled 
corticosteroid, only medication used to treat allergies prescribed, long acting β2-agonists 
prescribed with a leukotriene receptor antagonist and theophylline, oral steroids prescribed 
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without an inhaled corticosteroid, oral steroids prescribed without long acting β2-agonists, 
promethazine (Phenergan) prescribed which is not on the stepwise approach and 
combinations of the reasons above. 
 
Pulmonologists diagnosed and prescribed treatment for 343 patients of which 69 (20%) 
prescriptions did not follow the stepwise approach. The most common reason was the doctor 
prescribed a long acting β2-agonist with a leukotriene receptor antagonist which included 
prescriptions for 37 patients. Nineteen prescriptions did not follow the stepwise approach as 
anticholinergics were prescribed. Other reasons included Alcophyllex® and adrenaline 
prescribed for asthma which are not included on the stepwise approach, a long acting β2-
agonist prescribed with theophylline, a long acting β2-agonist, leukotriene receptor 
antagonist and theophylline prescribed together, only medication used to treat allergies was 
prescribed, promethazine prescribed for asthma which is not on the stepwise approach and 
combinations of reasons above. 
 
Specialist physicians prescribed treatment for 237 patients of which 77 (32%) prescriptions 
did not follow the stepwise approach. The main reason for this was a long acting β2-agonist 
was prescribed with a leukotriene receptor antagonist which included 35 prescriptions. 
Seventeen prescriptions included anticholinergics which are not included on the stepwise 
approach. Other reasons include cotrimoxazole prescribed to treat asthma, a long acting β2-
agonist prescribed with theophylline, a long acting β2-agonist prescribed with theophylline 
and a leukotriene receptor antagonist, a long acting β2-agonist and oral corticosteroids 
prescribed without an inhaled corticosteroid, oral steroids prescribed without a long acting 
β2-agonist or an inhaled corticosteroid, oxygen prescribed for asthma which is not included 
on the stepwise approach and a combination of the reasons above. 
 
Paediatricians prescribed treatment for 32 patients of which nine prescriptions did not follow 
the stepwise approach (28%). All nine of these prescriptions did not follow the stepwise 
approach as a long acting β2-agonist was prescribed with a leukotriene receptor antagonist. 
 
Cardiologists prescribed treatment for asthma for nine patients of which two prescriptions did 
not follow the stepwise approach as the doctor prescribed an anticholinergic.  
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Endocrinologists prescribed treatment for six patients of which two (33%) of the 
prescriptions did not follow the stepwise approach. The reasons include a long acting β2-
agonist prescribed with theophylline and a leukotriene receptor antagonist and only 
medication used to treat allergies was prescribed for asthma. 
 
ENT’s (Otorhinolaryngologists) prescribed medication for asthma for two patients. One of 
the prescriptions did not follow the stepwise approach as only medication used to treat 
allergies was prescribed for asthma. 
 
Nephrologists treated asthma in three patients of which one prescription did not follow the 
stepwise approach as the doctor prescribed an anticholinergic. 
 
Gastroenterologists prescribed medication for two patients, a neurologist diagnosed asthma 
for a patient, paediatric pulmonologists diagnosed and treated asthma for six patients, a 
psychiatrist diagnosed and prescribed treatment for one patient and a rheumatologist treated 
asthma for two patients. All of these doctors followed the stepwise approach. 
 
Table 6.6 shows the reasons the prescriptions prescribed from different providers did not 
follow the stepwise approach for the 12 years and older age group.  
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Table 6.6 Age 12 and older reasons providers did not follow the stepwise approach  
PROVIDER 
REASON PRESCRIPTION DID NOT FOLLOW THE STEPWISE 
APPROACH 
TOTAL 
Cardiologist Anticholinergic not on treatment guidelines 2 
Endocrinologist 
LABA or LTRA or theophylline but all prescribed 1 
Only allergy meds prescribed for asthma 1 
ENT Only meds for allergy prescribed 1 
General 
practitioner 
2 ICS prescribed 7 
Acc200 is not on the treatment guidelines and should be used 
with caution in asthmatics 1 
Anticholinergic not on treatment guidelines 51 
Anticholinergic not on treatment guidelines, 2 ICS prescribed 2 
LABA or LTRA but both prescribed 48 
LABA or LTRA but both prescribed, Anticholinergic not on 
treatment guidelines 3 
LABA or LTRA or the theophylline but all prescribed 1 
LABA or LTRA or theophylline but all prescribed, Anticholinergic 
not on treatment guidelines 1 
LABA or theophylline but both prescribed 17 
LABA or theophylline but both prescribed, Anticholinergic not on 
treatment guidelines 1 
LABA, LTRA or theophylline but all prescribed, 2 LABAs 
prescribed, Anticholinergic not on treatment guidelines  1 
LABA prescribed with no ICS 5 
LABA prescribed with no ICS, Anticholinergic not on treatment 
guidelines 1 
Only meds for allergy prescribed 9 
Oral steroids prescribed without ICS 1 
Oral steroids prescribed without LABA 1 
Promethazine is not on the treatment guidelines 1 
Nephrologist Anticholinergic not on treatment guidelines 1 
Paediatrician LABA or LTRA but both prescribed 9 
Pulmonologist 
Alcophyllex and adrenaline not in treatment guidelines 1 
Anticholinergic not on treatment guidelines 19 
Anticholinergic not on treatment guidelines, either LABA or 
theophylline but both prescribed 1 
LABA or LTRA but both prescribed 37 
LABA or LTRA but both prescribed, Anticholinergic not on 
treatment guidelines 2 
LABA or LTRA or theophylline but all prescribed 1 
LABA or theophylline but both prescribed 3 
Only meds for allergy prescribed 3 
Promethazine is not on the treatment guidelines 2 
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PROVIDER 
REASON PRESCRIPTION DID NOT FOLLOW THE STEPWISE 
APPROACH 
TOTAL 
Specialist 
physician 
Anticholinergic not on treatment guidelines 17 
LABA or LTRA but both prescribed 35 
LABA or LTRA but both prescribed, Forvent not on the treatment 
guideline 1 
LABA or LTRA but both prescribed, Purbac not on the treatment 
guidelines 1 
LABA or LTRA or theophylline but all prescribed 4 
LABA or LTRA or theophylline but all prescribed, Anticholinergic 
not on treatment guidelines 2 
LABA or theophylline but both prescribed 7 
LABA or theophylline but both prescribed, Anticholinergic not on 
treatment guidelines 2 
LABA and oral corticosteroid without ICS 1 
LABA prescribed with no ICS 3 
Oral steroids prescribed without ICS 1 
Oral steroids prescribed without LABA or ICS 2 
Oxygen is not on the treatment guidelines 1 
KEY: LABA = Long acting β2-agonist, ICS = Inhaled corticosteroid, LTRA = Leukotriene 
receptor antagonist  
 
Table 6.7 shows the comparison between the prescriber and the number of patients, whose 
treatment prescribed for these patients diagnosed with first time asthma, did not follow the 
stepwise approach. This is divided into each age group. This table does not take into account 
the total number of prescriptions completed by each provider. In the age group 0-4 years, the 
paediatricians had the highest number of treatments prescribed that did not follow the 
stepwise approach. In the age group 5-11 years, the most number of prescriptions which did 
not follow the stepwise approach was prescribed by paediatricians. In the age group 12 years 
and older, the most number of prescriptions which did not follow the stepwise approach came 
from general practitioners but general practitioners also had the greatest number of 
prescriptions completed in the age group.  
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Table 6.7 Total number of prescriptions which did not follow the stepwise approach 
AGE PROVIDER TOTAL 
0-4 
General practitioner 36 
Paediatric pulmonologist 12 
Paediatrician 189 
Pulmonologist 3 
5-11 
General practitioner 37 
Paediatric pulmonologist 7 
Paediatrician 88 
Pulmonologist 2 
Specialist physician 0 
12-
Adult 
Cardiologist 2 
Endocrinologist 2 
ENT 1 
Gastroenterologist 0 
General practitioner 151 
Nephrologist 1 
Neurologist 0 
Paediatric pulmonologist 0 
Paediatrician 9 
Psychiatrist 0 
Pulmonologist 69 
Rheumatologist 0 
Specialist physician 77 
 
This research project was looking at prescribing patterns and looking at whether doctors were 
following guidelines and the stepwise approach when treating patients with asthma. Out of 
the 3639 patients, 2953 (81%) patients were diagnosed with first time asthma following the 
stepwise approach for treatment. 686 (19%) patients were prescribed medicine that did not 
follow the stepwise approach. The patients with co-morbidities whose treatment did not 
follow the stepwise approach was 20%, so the fact that patients diagnosed with other chronic 
conditions did not influence prescribing patterns too much compared to the whole patient 
population. 
 
1760 prescriptions came from general practitioners of which 224 (13%) prescriptions did not 
follow the stepwise approach. Pulmonologists sent through 373 of the prescriptions to the 
medical aid of which 74 (20%) of these prescriptions did not follow the stepwise approach. 
Specialist physicians had a total of 241 of the prescriptions of which 77 (32%) prescriptions 
did not follow the stepwise approach. Paediatricians sent through a total of 1121 prescriptions 
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of which 286 (26%) did not follow the stepwise approach. Paediatric pulmonologists 
prescribed a total of 118 prescriptions of which nineteen (16%) of the prescriptions did not 
follow the stepwise approach. This would indicate that general practitioners prescribed 
treatment which followed the stepwise approach best and specialist physicians prescribed 
treatment for patients with asthma the worst in terms of following the stepwise approach. It is 
difficult to say best and worst as it is difficult to see all aspects of the patient. Allergies are 
not taken into consideration and specialists are more likely to see complicated patients in 
which standard treatment may not be indicated. The patients’ age and co-morbidities that are 
not approved from the medical aid, and therefore not taken into consideration, are also 
factors. 
 
From another study it was concluded that a large proportion of drugs prescribed for asthma 
are not according to the recommended guidelines of the Department of Health or the expert 
guideline recommendations for asthma management (Steyn, 2006). 
 
In all age groups general practitioners followed the stepwise approach best but they had the 
most variation in terms of reasons why this provider type did not follow the stepwise 
approach. In the age group 0-4 years, pulmonologists followed the stepwise approach the 
worst but again these are specialists in pulmonology and may be seeing complicated patients. 
In the age group 5-11 years, paediatricians had the highest percentage of prescriptions that 
did not follow the stepwise approach. In the age group 12 years and older, specialist 
physicians had the highest percentage of prescriptions that did not follow the stepwise 
approach. In the adult population other prescribers like gastroenterologists, neurologists and 
nephrologist may have diagnosed patients with asthma as they were treating these patients for 
other conditions. 
 
The standard treatment guideline for chronic persistent asthma says that maintenance therapy 
includes inhaled corticosteroids which are the mainstay of treatment in chronic asthma (The 
National Department of Health, 2012). Reliever or rescue therapy includes β2-agonists like 
salbutamol. If there is insufficient response to adequate steroids and salbutamol the doctor 
may add theophylline modified release tablets. If asthma is still not well controlled the doctor 
may add a short course of a long acting β2-agonist therapy like formoterol. On failure of this 
therapy the doctor may add prednisone tablets. This is very similar to the stepwise approach 
except that long acting β2-agonists are used in combination with inhaled corticosteroids as 
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maintenance therapy and leukotriene receptor antagonists can be used in place of 
theophylline.  
 
7.  LIMITATIONS  
 
There are a few limitations of this study: 
 The information obtained in this project will not reflect the greater population; the 
information is not generalizable to the greater population or to other Medical Aids.  
 Data is only as good as what is provided on the application form and database for 
patients, so some information may be missing.  
 Depending on the plan type, not all doctors’ visits or medication may be reflecting on 
the database.  
 The doctor who diagnosed the patient may not be the same doctor who filled in the 
Chronic Application Form so we may document prescribing patterns from the 
incorrect doctor when looking at what type of doctor prescribed the medication.  
 The doctor may have only filled in the chronic application form when the patient was 
controlled on the medication so this may not be the initial treatment the patient was 
prescribed. The patient may have been taking acute medication so the system may 
skew the data. 
 Not all doctors submit Lung Function Tests so documenting the information from the 
Lung Function Tests may be inaccurate as it will not reflect all the patients which 
have been looked at. 
 It is difficult to get the full picture in terms of treatment for the patient and severity 
from limited information provided by the Medical Aid. 
 Patients may have had other tests done which were not submitted to the Medical Aid 
and have therefore not been included. 
 Honesty on the application form cannot be confirmed so a doctor may say the patient 
has just been diagnosed with the condition to avoid penalisation but may have had the 
condition for many years. 
 Prescribers may prescribed medicine for asthma as the condition will be approved as 
there is no clinical entry criteria, whereas other conditions, like chronic obstructive 
pulmonary disease, has got clinical entry criteria for approval and allergic rhinitis is 
not a PMB condition. 
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8. RECOMMENDATION 
 
The findings of the study will be presented to the Medical Aid. 
 
Follow-up studies need to be done to determine the reasons why so many patients were 
initiated on more than two medicines and why adults were diagnosed at a late stage of their 
lives. 
 
Follow-up studies are also recommended to evaluate prescriptions against patient information 
with the prescribers directly to review the clinical picture of patients diagnosed. 
 
9. CONCLUSION 
 
Asthma is a complicated disease. Patients have different symptoms, have co-morbidities and 
are on medication to treat other conditions. The goal of treatment for patients suffering with 
asthma is to get the patient back to normal lung function, prevent irreversible lung damage 
and prevent asthma attacks.  Patients should continue with life as they once did before their 
diagnosis of asthma. It is difficult to say that the prescription is wrong as it does not follow 
the stepwise approach as it is difficult to see the whole picture with bits of information that 
has been received from a medical aid.  
 
The total patient population for this study was 3639 patients; from this total 2953 (81%) 
patients were diagnosed with first time asthma following the stepwise approach for treatment. 
686 patients were diagnosed with first time asthma and did not follow the stepwise approach 
for treatment which is 19% of the patient population. The patients with co-morbidities whose 
treatment did not following the stepwise approach was 20% so the fact that patients 
diagnosed with other chronic conditions did not influence prescribing patterns too much 
compared to the whole patient population. 
 
49% of the chronic application forms came from general practitioners, 31% from 
paediatricians, 10% from pulmonologists, 7% from specialist physicians and 3% of 
applications came from paediatric pulmonologists. Specialists are prescribing more than two 
Page 53 of 56 
 
medicines per prescription for asthma for an initial diagnosis with general practitioners 
prescribing one or two items on the prescription for asthma. 
 
From the patient population 1853 (51%) are female and 1786 (49%) are male. The mean age 
of the patient population is 23.5 years old. Fifty percent of the patients are younger than 12 
years of age with most of the patients less than five years. 
 
Treatment of patients diagnosed with asthma should be the responsibility of all healthcare 
providers to ensure the best outcome of the patients so that the patient can return to normal 
function. 
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